This mAb (F9H4) retains CD16a on the NK cell and macrophage surface and CD16b on the neutrophil surface, is not an agonist or blocker, and synergizes with cetuximab to promote ADCC against lung cancer cells and inhibit tumor growth. Here, FCGR3A is linked to lung carcinoma.